{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:46:16Z","timestamp":1792806376179,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015722","name":"Centre Hospitalier Universitaire de Clermont-Ferrand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-factor Xa assays and activated partial thromboplastin time (aPTT) are mainly employed to monitor patients treated with heparins. According to the Clinical and Laboratory Standards Institute and the French Working Group on Haemostasis and Thrombosis, anti-factor Xa activity and aPTT should be tested within 2\u00a0h of blood sampling for unfractionated heparin (UFH) monitoring. However, discrepancies exist depending on the used reagents and collecting tubes. The study aim was to determine the stability of aPTT and anti-factor Xa measurements using blood samples collected in citrate-containing or citrate-theophylline-adenosine-dipyridamole (CTAD) tubes and stored for up to 6\u00a0h.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients receiving UFH or low molecular weight heparin (LMWH) were enrolled; aPTT and anti-factor Xa activity were tested using two different analyser\/reagent pairs (Stago and reagent without dextran sulfate; Siemens and reagent with dextran sulfate) after 1, 4 and 6\u00a0h of sample storage as whole blood or as plasma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For UFH monitoring, comparable anti-factor Xa activity and aPTT results were obtained with both analyser\/reagent pairs when samples were stored as whole blood before plasma isolation. With samples stored as plasma, anti-factor Xa activity and aPTT were not affected up to 6\u00a0h after sampling when using the Stago\/no-dextran sulfate reagent pair. With the Siemens\/dextran sulfate-containing reagent, aPTT was significantly altered after 4\u00a0h of storage. For LMWH monitoring, anti-factor Xa activity remained stable (whole blood and plasma) for at least 6\u00a0h. Results were comparable with citrate-containing and CTAD tubes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anti-factor Xa activity in samples stored as whole blood or plasma was stable for up to 6\u00a0h, regardless of the reagent (with\/without dextran sulfate)\/collection tube. Conversely, aPTT was more variable because other plasma parameters can influence its measure and complicate the interpretation of its variations after 4\u00a0h.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-023-00465-8","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T13:18:27Z","timestamp":1676899107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes"],"prefix":"10.1186","volume":"21","author":[{"given":"Marion","family":"Gremillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Talon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Lebreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sinegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"issue":"5432","key":"465_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/246355a0","volume":"246","author":"PS Damus","year":"1973","unstructured":"Damus PS, Hicks M, Rosenberg RD. Anticoagulant Action of Heparin. Nature. 1973;246(5432):355\u20137.","journal-title":"Nature"},{"issue":"1","key":"465_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/clpt.1982.16","volume":"31","author":"TD Bjornsson","year":"1982","unstructured":"Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982;31(1):104\u201313.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"465_CR3","doi-asserted-by":"publisher","first-page":"e24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants. Chest. 2012;141(2):e24S-e43S.","journal-title":"Chest"},{"issue":"23","key":"465_CR4","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1161\/01.CIR.0000077530.53367.E9","volume":"107","author":"SS Anand","year":"2003","unstructured":"Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Organization to Assess Strategies for Ischemic Syndromes Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003;107(23):2884\u20138.","journal-title":"Circulation."},{"issue":"3","key":"465_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1378\/chest.126.3_suppl.188S","volume":"126","author":"J Hirsh","year":"2004","unstructured":"Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3):188\u2013203.","journal-title":"Chest."},{"issue":"6","key":"465_CR6","doi-asserted-by":"publisher","first-page":"141S","DOI":"10.1378\/chest.08-0689","volume":"133","author":"J Hirsh","year":"2008","unstructured":"Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral Anticoagulants. Chest. 2008;133(6):141S-159S.","journal-title":"Chest"},{"key":"465_CR7","unstructured":"Clinical and Laboratory Standards Institute. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays: approved guideline-Fifth Edition. Approved Guideline-Fifth Edition. Wayne, PA.: CLSI; 2008. (CLSI document H21-A5). https:\/\/clsi.org\/media\/1399\/h21a5_sample.pdf."},{"key":"465_CR8","unstructured":"Boissier E, Calmette L, Delahousse B, Flaujac C, Fran\u00e7oise M, Mauge L. Recommandations pr\u00e9analytiques en h\u00e9mostase\u202f: Stabilit\u00e9 des param\u00e8tres d\u2019h\u00e9mostase g\u00e9n\u00e9rale et d\u00e9lais de r\u00e9alisation des examens. 2017;29. https:\/\/site.geht.org\/app\/uploads\/2017\/06\/Recommandations-texte-long-GFHT-d%C3%A9lai-de-r%C3%A9alisation_V240517.pdf."},{"issue":"2","key":"465_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11239-019-01882-1","volume":"48","author":"P Billoir","year":"2019","unstructured":"Billoir P, Clavier T, Guilbert A, Barbay V, Chr\u00e9tien MH, Fresel M, et al. Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey? J Thromb Thrombolysis. 2019;48(2):277\u201383.","journal-title":"J Thromb Thrombolysis"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2019.10.019","volume":"186","author":"P Toulon","year":"2020","unstructured":"Toulon P, Appert-Flory A, Fischer F, Buvat S, Jambou D, Mahagne MH. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes. Thromb Res. 2020;186:7\u201312.","journal-title":"Thromb Res"},{"issue":"5","key":"465_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1365-2141.2011.08745.x","volume":"155","author":"N Birri","year":"2011","unstructured":"Birri N, Baumgartner D, Conte T, Huynh A, Weller K, Pavicic M, et al. Stability of low molecular weight heparin anti-factor Xa activity in citrated whole blood and plasma: Correspondence. Br J Haematol. 2011;155(5):629\u201331.","journal-title":"Br J Haematol"},{"issue":"3","key":"465_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1076029609336853","volume":"16","author":"P Rojnuckarin","year":"2010","unstructured":"Rojnuckarin P, Akkawat B, Juntiang J. Stability of Plasma Anti-Xa Activity in Low-Molecular-Weight Heparin Monitoring. Clin Appl Thromb Hemost. 2010;16(3):313\u20137.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"465_CR13","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1111\/jth.14969","volume":"18","author":"M Smahi","year":"2020","unstructured":"Smahi M, De Pooter N, Hollestelle MJ, Toulon P. Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents. J Thromb Haemost. 2020;18(10):2613\u201321.","journal-title":"J Thromb Haemost"},{"issue":"4\u20135","key":"465_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.thromres.2003.09.014","volume":"111","author":"C Mouton","year":"2003","unstructured":"Mouton C, Calderon J, Janvier G, Vergnes MC. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine. Thromb Res. 2003;111(4\u20135):273\u20139.","journal-title":"Thromb Res"},{"issue":"2","key":"465_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1042\/bj2090455","volume":"209","author":"J Denton","year":"1983","unstructured":"Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J. 1983;209(2):455\u201360.","journal-title":"Biochem J"},{"issue":"5\u20136","key":"465_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/10245330500397752","volume":"11","author":"MA Awad","year":"2006","unstructured":"Awad MA, Sharaf Eldeen OA, Ibrahim HA. Stability of activated partial thromboplastin time (APTT) test under different storage conditions. Hematology. 2006;11(5\u20136):311\u20135.","journal-title":"Hematology"},{"issue":"6","key":"465_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00001721-199809000-00002","volume":"9","author":"D Adcock","year":"1998","unstructured":"Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis. 1998;9(6):463\u201370.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"10","key":"465_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1538-7836.2008.03101.x","volume":"6","author":"M Ray","year":"2008","unstructured":"Ray M. Stability of the activated partial thromboplastin time used to monitor unfractionated heparin. J Thromb Haemost. 2008;6(10):1817\u20139.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"465_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.thromres.2006.10.006","volume":"120","author":"V Ignjatovic","year":"2007","unstructured":"Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate? Thromb Res. 2007;120(3):347\u201351.","journal-title":"Thromb Res"},{"issue":"5","key":"465_CR20","first-page":"547","volume":"96","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96(5):547\u201352.","journal-title":"Thromb Haemost"},{"issue":"7","key":"465_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1515\/CCLM.1998.077","volume":"36","author":"W Heil","year":"1998","unstructured":"Heil W, Grunewald R, Amend M, Heins M. Influence of Time and Temperature on Coagulation Analytes in Stored Plasma. Clin Chem Lab Med. 1998;36(7):459\u201362.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"465_CR22","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/srep03868","volume":"4","author":"L Feng","year":"2015","unstructured":"Feng L, Zhao Y, Zhao H, Shao Z. Effects of storage time and temperature on coagulation tests and factors in fresh plasma. Sci Rep. 2015;4(1):3868.","journal-title":"Sci Rep"},{"key":"465_CR23","doi-asserted-by":"crossref","unstructured":"Rozen L, Copette F, Noubouossie D, Demulder A. Evaluation of Three APTT Reagents in a Routine Laboratory: Toward a\u00a0Compromise. Clin Lab. 2013;59(7-8):921-4.","DOI":"10.7754\/Clin.Lab.2012.120909"},{"issue":"2","key":"465_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0049-3848(83)90337-7","volume":"31","author":"G Contant","year":"1983","unstructured":"Contant G, Gouault-Heilmann M, Martinoli JL. Heparin inactivation during blood storage\u202f: Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole -C.T.A.D. mixture-. Thromb Res. 1983;31(2):365\u201374.","journal-title":"Thromb Res"},{"issue":"02","key":"465_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1055\/s-0038-1651099","volume":"57","author":"AMHP van den Besselaar","year":"1987","unstructured":"van den Besselaar AMHP, Meeuwisse-Braun J, Jansen-Gr\u00fcter R, Bertina RM. Monitoring Heparin Therapy by the Activated Partial Thromboplastin Time - The Effect of Pre-Analytical Conditions. Thromb Haemost. 1987;57(02):226\u201331.","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-023-00465-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-023-00465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T13:26:19Z","timestamp":1676899579000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-023-00465-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1186\/s12959-023-00465-8","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was performed in accordance with the French authorities and approved by the Clermont-Ferrand university hospital ethical committee (CPP Sud-Est VI, ref. AU765) in which patients consent to participate and to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}